Absci and MSK Collaborate on Generative AI Drug Discovery

Absci Corporation, an AI drug creation firm, has partnered with the Memorial Sloan Kettering Cancer Center to develop six novel cancer treatments. Using Absci’s AI platform and MSK’s cancer research knowledge, the collaborators aim to fast-track the discovery and development of new therapies, with targets for preclinical development expected by end-2024. Absci’s portfolio includes almost $1bn in drug discovery deals made in the past year.